Marc Sanson
Marc Sanson
Neurologist, Sorbonne-Université
Підтверджена електронна адреса в
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2
GA Rouleau, P Merel, M Lutchman, M Sanson, J Zucman, C Marineau, ...
Nature 363 (6429), 515, 1993
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas
M Sanson, Y Marie, S Paris, A Idbaih, J Laffaire, F Ducray, S El Hallani, ...
J Clin Oncol 27 (25), 4150-4154, 2009
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and …
MJ van den Bent, AF Carpentier, AA Brandes, M Sanson, MJB Taphoorn, ...
Journal of Clinical Oncology 24 (18), 2715-22, 2006
Genome-wide association study identifies five susceptibility loci for glioma
S Shete, FJ Hosking, LB Robertson, SE Dobbins, M Sanson, B Malmer, ...
Nature genetics 41 (8), 899, 2009
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of …
MJ Van den Bent, HJ Dubbink, Y Marie, AA Brandes, MJB Taphoorn, ...
Clinical Cancer Research 16 (5), 1597-1604, 2010
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
C Houillier, X Wang, G Kaloshi, K Mokhtari, R Guillevin, J Laffaire, S Paris, ...
Neurology 75 (17), 1560-1566, 2010
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions
K Hoang-Xuan, L Capelle, M Kujas, S Taillibert, H Duffau, J Lejeune, ...
Journal of clinical oncology 22 (15), 3133-3138, 2004
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome
G Kaloshi, A Benouaich-Amiel, F Diakite, S Taillibert, J Lejeune, ...
Neurology 68 (21), 1831-1836, 2007
A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry
S El Hallani, B Boisselier, F Peglion, A Rousseau, C Colin, A Idbaih, ...
Brain 133 (4), 973-982, 2010
MGMT testing—the challenges for biomarker-based glioma treatment
W Wick, M Weller, M Van Den Bent, M Sanson, M Weiler, A Von Deimling, ...
Nature Reviews Neurology 10 (7), 372, 2014
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group …
MJ van den Bent, HJ Dubbink, M Sanson, CR van der Lee-Haarloo, ...
Journal of Clinical Oncology 27 (35), 5881, 2009
Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1) A retrospective study of 104 patients
JS Guillamo, A Creange, C Kalifa, J Grill, D Rodriguez, F Doz, S Barbarot, ...
Brain 126 (1), 152-160, 2002
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle …
C Soussain, K Hoang-Xuan, L Taillandier, E Fourme, S Choquet, F Witz, ...
Journal of clinical oncology 26 (15), 2512-2518, 2008
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
M Labussiere, A Idbaih, XW Wang, Y Marie, B Boisselier, C Falet, S Paris, ...
Neurology 74 (23), 1886-1890, 2010
MGMT methylation: a marker of response to temozolomide in low‐grade gliomas
S Everhard, G Kaloshi, E Criniere, A Benouaich‐Amiel, J Lejeune, ...
Annals of Neurology: Official Journal of the American Neurological …, 2006
Genome-wide association study of glioma and meta-analysis
P Rajaraman, BS Melin, Z Wang, R McKean-Cowdin, DS Michaud, ...
Human genetics 131 (12), 1877-1888, 2012
Dynamic history of low‐grade gliomas before and after temozolomide treatment
D Ricard, G Kaloshi, A Amiel‐Benouaich, J Lejeune, Y Marie, ...
Annals of Neurology: Official Journal of the American Neurological …, 2007
Clinical trial of blood-brain barrier disruption by pulsed ultrasound
A Carpentier, M Canney, A Vignot, V Reina, K Beccaria, C Horodyckid, ...
Science translational medicine 8 (343), 343re2-343re2, 2016
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
A Carpentier, F Laigle-Donadey, S Zohar, L Capelle, A Behin, A Tibi, ...
Neuro-oncology 8 (1), 60-66, 2006
Two types of chromosome 1p losses with opposite significance in gliomas
A Idbaih, Y Marie, G Pierron, C Brennetot, K Hoang‐Xuan, M Kujas, ...
Annals of neurology 58 (3), 483-487, 2005
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20